Nitric Oxide Bioavailability and Its Potential Relevance to the Variation in Susceptibility to the Renal and Vascular Complications in Patients With Type 2 Diabetes
- Kenneth A. Earle, MD1,
- Diane Harry, RGN1,
- Mitra Madhavi, MBBS1,
- Karima Zitouni, PHD1 and
- Jeffrey Barron, PHD2
- 1University College London Medical School, Whittington Hospital, London, U.K.
- 2St Helier Hospital, Carshalton, U.K.
- Corresponding author: Kenneth A. Earle, k.earle{at}sgul.ac.uk
Abstract
OBJECTIVE—We compared the renal and systemic vascular (renovascular) response to a reduction of bioavailable nitric oxide (NO) in type 2 diabetic patients without nephropathy and of African and Caucasian heritage.
RESEARCH DESIGN AND METHODS—Under euglycemic conditions, renal blood flow was determined by a constant infusion of paraminohippurate and changes in blood pressure and renal vascular resistance estimated before and after an infusion of l-Ng-monomethyl-l-arginine.
RESULTS—In the African-heritage group, there was a significant fall in renal blood flow (Δ−46.0 ml/min per 1.73 m2; P < 0.05) and rise in systolic blood pressure (Δ10.0 mmHg [95% CI 2.3–17.9]; P = 0.017), which correlated with an increase in renal vascular resistance (r2 = 0.77; P = 0.004).
CONCLUSIONS—The renal vasoconstrictive response associated with NO synthase inhibition in this study may be of relevance to the observed vulnerability to renal injury in patients of African heritage.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 22 October 2008.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted October 13, 2008.
- Received May 13, 2008.
- DIABETES CARE
